Once-Monthly Long-Acting Injectable Aripiprazole for the Treatment of Patients with Schizophrenia and Co-occurring Substance Use Disorders: A Multicentre, Observational Study

• Main Authors: Nestor Szerman (Author), Ignacio Basurte-Villamor (Author), Pablo Vega (Author), Jose Martinez-Raga (Author), Carlos Parro-Torres (Author), Julia Cambra Almerge (Author), Lara Grau-López (Author), Mario De Matteis (Author), Francisco Arias (Author)
• Format: Book
• Published: Adis, Springer Healthcare, 2020-02-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Aim To evaluate the efficacy and impact of long-acting injectable (LAI) aripiprazole in patients with schizophrenia with a coexisting substance use disorder (SUD). Patients and methods A multicenter, observational, descriptive and retrospective study was conducted in patients with a DSM-5 d...